TP53 and acute myeloid leukemia: The 2022 findings of European LeukemiaNet support the consideration of a TP53 mutation as a distinct AML entity with a “very-adverse” risk profile like that listed for European LeukemiaNet in the 2022 International Consensus Classification (Tashakori et al., 2022; Fleming et al., 2023).